Top

Published in:

01-01-2014 | Original Article

Peptide-based inhibition of the HOXA9/PBX interaction retards the growth of human meningioma

Authors: Hitoshi Ando, Atsushi Natsume, Takeshi Senga, Reiko Watanabe, Ichiro Ito, Masasuke Ohno, Kenichiro Iwami, Fumiharu Ohka, Kazuya Motomura, Sayano Kinjo, Maki Ito, Kiyoshi Saito, Richard Morgan, Toshishiko Wakabayashi

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2014

Abstract

Background

Meningiomas are the most common type of intracranial tumor, accounting for between 24 and 30 % of primary intracranial tumors. Thus far, no biomarkers exist to reliably predict the clinical outcome of meningiomas. A previous genome-wide methylation analysis revealed that HOXA9 is one of the most functionally relevant biomarkers. In this study, we have examined whether HOXA9 is a potential therapeutic target in meningiomas, using HXR9, a peptide inhibitor of the interaction between HOXA9 and its cofactor PBX.

Methods

We determined the expression level of HOXA9 in human meningiomas, meningioma cell lines, and normal brain tissue. Meningioma in culture and in subcutaneous tumors was treated with HXR9. We also examined the disruption of HOXA9/PBX dimers.

Results

We first confirmed that HOXA9 is highly expressed in meningiomas, but not in normal brain tissue. The HXR9 peptide blocks the binding of HOXA9 to PBX, leading to an alteration of DNA binding, and subsequent regulation of their target genes. HXR9 markedly inhibited the growth of meningioma cells and subcutaneous meningeal tumors.

Conclusion

There is no effective chemotherapy for meningiomas at present, and targeting the HOXA9/PBX interaction may represent a novel treatment option for this disease.

Abe M, Hamada J, Takahashi O, Takahashi Y, Tada M, Miyamoto M, Morikawa T, Kondo S, Moriuchi T (2006) Disordered expression of HOX genes in human non-small cell lung cancer. Oncol Rep 15:797–802PubMed

Aghi MK, Carter BS, Cosgrove GR, Ojemann RG, Amin-Hanjani S, Martuza RL, Curry WT Jr, Barker FG (2009) Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 64:56–60PubMedCrossRef

Andrae N, Kirches E, Hartig R, Haase D, Keilhoff G, Kalinski T, Mawrin C (2012) Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells. Euro J Cancer 48:1831–1841CrossRef

Backer-Grøndahl T, Moen BH, Torp SH (2012) The histopathological spectrum of human meningiomas. Int J Clin Exp Pathol 5:231PubMedCentralPubMed

Cantile M, Procino A, D’Armiento M, Cindolo L, Cillo C (2003) HOX gene network is involved in the transcriptional regulation of in vivo human adipogenesis. J Cell Physiol 194:225–236PubMedCrossRef

Costa BM, Smith JS, Chen Y, Chen J, Phillips HS, Aldape KD, Zardo G, Nigro J, James CD, Fridlyand J, Reis RM, Costello JF (2010) Reversing HOXA9 oncogene activation by PI3 K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res 70:453–462PubMedCentralPubMedCrossRef

Daniels TR, Neacato II, Rodriguez JA, Pandha HS, Morgan R, Penichet ML (2010) Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells. Leuk Off J Leuk Soc Am Leuk Res Fund U.K 24:1555–1565CrossRef

Durston AJ (2011) Hox homeotic selector genes: key regulators of embryogenesis. WebmedCentral EMBRYOLOGY 2:WMC002573

Eichhorst ST, Muller M, Li-Weber M, Schulze-Bergkamen H, Angel P, Krammer PH (2000) A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol Cell Biol 20:7826–7837PubMedCentralPubMedCrossRef

10.

Eklund EA (2007) The role of HOX genes in malignant myeloid disease. Cur Opin Hematol 14:85–89CrossRef

11.

Grier D, Thompson A, Kwasniewska A, McGonigle G, Halliday H, Lappin T (2005) The pathophysiology of HOX genes and their role in cancer. J Pathol 205:154–171PubMedCrossRef

12.

Hoegg S, Meyer A (2005) Hox clusters as models for vertebrate genome evolution. Trends Genet 21:421–424

13.

Huang Y, Sitwala K, Bronstein J, Sanders D, Dandekar M, Collins C, Robertson G, MacDonald J, Cezard T, Bilenky M, Thiessen N, Zhao Y, Zeng T, Hirst M, Hero A, Jones S, Hess JL (2012) Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood 119:388–398PubMedCrossRef

14.

Iimura T, Pourquié O (2007) Hox genes in time and space during vertebrate body formation. Dev Growth Differ 49:265–275PubMedCrossRef

15.

Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR (1998) DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell 1:543–551PubMedCrossRef

16.

Kishida Y, Natsume A, Kondo Y, Takeuchi I, An B, Okamoto Y, Shinjo K, Saito K, Ando H, Ohka F (2012) Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses. Carcinogenesis 33:436–441PubMedCrossRef

17.

Ko SY, Barengo N, Ladanyi A, Lee JS, Marini F, Lengyel E, Naora H (2012) HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J Clin Investig 122:3603–3617PubMedCrossRef

18.

Laurent A, Bihan R, Omilli F, Deschamps S, Pellerin I (2008) PBX proteins: much more than Hox cofactors. Int J Dev Biol 52:9PubMedCrossRef

19.

Maier H, Öfner D, Hittmair A, Kitz K, Budka H (1992) Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance. J Neurosurg 77:616–623PubMedCrossRef

20.

McIntyre DC, Rakshit S, Yallowitz AR, Loken L, Jeannotte L, Capecchi MR, Wellik DM (2007) Hox patterning of the vertebrate rib cage. Development 134:2981–2989PubMedCrossRef

21.

Miller GJ, Miller HL, van Bokhoven A, Lambert JR, Werahera PN, Schirripa O, Lucia MS, Nordeen SK (2003) Aberrant HOXC expression accompanies the malignant phenotype in human prostate. Cancer Res 63:5879–5888PubMed

22.

Moens CB, Selleri L (2006) Hox cofactors in vertebrate development. Dev Biol 291:193–206PubMedCrossRef

23.

Morgan R, Boxall A, Harrington KJ, Simpson GR, Gillett C, Michael A, Pandha HS (2012) Targeting the HOX/PBX dimer in breast cancer. Breast Cancer Res Treat 136:389–398

24.

Morgan R, Pirard PM, Shears L, Sohal J, Pettengell R, Pandha HS (2007) Antagonism of HOX/PBX dimer formation blocks the in vivo proliferation of melanoma. Cancer Res 67:5806PubMedCrossRef

25.

Morgan R, Plowright L, Harrington KJ, Michael A, Pandha HS (2010) Targeting HOX and PBX transcription factors in ovarian cancer. BMC Cancer 10:89PubMedCentralPubMedCrossRef

26.

Plowright L, Harrington K, Pandha H, Morgan R (2009) HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer). Br J Cancer 100:470–475PubMedCentralPubMedCrossRef

27.

Rich KA, Zhan Y, Blanks JC (1997) Aberrant expression of c-Fos accompanies photoreceptor cell death in the rd mouse. J Neurobiol 32:593–612PubMedCrossRef

28.

Shears L, Plowright L, Harrington K, Pandha HS, Morgan R (2008) Disrupting the interaction between HOX and PBX causes necrotic and apoptotic cell death in the renal cancer lines CaKi-2 and 769-P. J Urol 180:2196–2201PubMedCrossRef

29.

30.

Waltregny D, Alami Y, Clausse N, de Leval J, Castronovo V (2002) Overexpression of the homeobox gene HOXC8 in human prostate cancer correlates with loss of tumor differentiation. Prostate 50:162–169PubMedCrossRef

31.

Watanabe R, Nakasu Y, Tashiro H, Mitsuya K, Ito I, Nakasu S, Nakajima T (2011) O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma. Brain Tumor Pathol 28:127–135PubMedCrossRef

32.

Yaskiv O, Rubin BP, He H, Falzarano S, Magi-Galluzzi C, Zhou M (2012) ERG protein expression in human tumors detected with a rabbit monoclonal antibody. Am J Clin Pathol 138:803–810PubMedCrossRef

Title: Peptide-based inhibition of the HOXA9/PBX interaction retards the growth of human meningioma
Authors: Hitoshi Ando
Atsushi Natsume
Takeshi Senga
Reiko Watanabe
Ichiro Ito
Masasuke Ohno
Kenichiro Iwami
Fumiharu Ohka
Kazuya Motomura
Sayano Kinjo
Maki Ito
Kiyoshi Saito
Richard Morgan
Toshishiko Wakabayashi
Publication date: 01-01-2014
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2014
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-013-2316-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2014

The effect of chemotherapy with cisplatin and pemetrexed for choroidal metastasis of non-squamous cell carcinoma

Toll-like receptor signaling regulates cisplatin-induced mechanical allodynia in mice

Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients

A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer

Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers

E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer